Literature DB >> 15180868

Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack.

Dominick J H McCabe1, Paul Harrison, Ian J Mackie, Paul S Sidhu, Gordon Purdy, Andrew S Lawrie, Hilary Watt, Martin M Brown, Samuel J Machin.   

Abstract

Flow cytometric studies suggest that platelets are activated in ischaemic stroke or transient ischaemic attack (TIA). However, few studies have measured circulating leucocyte-platelet complexes in this patient population. Whole blood flow cytometry was used to quantify the expression of CD62P-, CD63-, and PAC1-binding, and the percentages of leucocyte-platelet complexes in acute (1-27 d, n = 79) and convalescent (79-725 d, n = 70) ischaemic cerebrovascular disease (CVD) patients compared with controls without CVD (n = 27). We performed a full blood count, and measured plasma levels of soluble P-selectin, soluble E-selectin, and von Willebrand factor antigen (VWF:Ag) as additional markers of platelet and/or endothelial cell activation. The median percentage CD62P expression and the median percentage monocyte-platelet complexes were higher in both acute and convalescent CVD patients than controls (P </= 0.02). The mean white cell count and mean VWF:Ag levels were significantly elevated in the acute and convalescent phases after ischaemic stroke or TIA (P </= 0.02). Otherwise, there was no significant increase in any other marker of platelet or endothelial activation in CVD patients. There was a positive correlation between the percentage expression of CD62P and the percentages of both neutrophil-platelet and monocyte-platelet complexes in the acute phase, and the percentages of all leucocyte-platelet complexes in the convalescent phase after ischaemic CVD. This study provides evidence for ongoing excessive platelet and/or endothelial activation in ischaemic CVD patients despite treatment with antithrombotic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180868     DOI: 10.1111/j.1365-2141.2004.04983.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  30 in total

1.  Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis.

Authors:  D J H McCabe; P Harrison; I J Mackie; P S Sidhu; G Purdy; A S Lawrie; H Watt; S J Machin; M M Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

2.  Longitudinal assessment of von Willebrand factor antigen and von Willebrand factor propeptide in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

3.  Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial.

Authors:  Rebecca Y Klinger; Mary Cooter; Miles Berger; Mihai V Podgoreanu; Mark Stafford-Smith; Thomas L Ortel; Ian J Welsby; Jerrold H Levy; Henry M Rinder; Mark F Newman; Joseph P Mathew
Journal:  Can J Anaesth       Date:  2016-07-28       Impact factor: 5.063

4.  Simultaneous assessment of plaque morphology, cerebral micro-embolic signal status and platelet biomarkers in patients with recently symptomatic and asymptomatic carotid stenosis.

Authors:  Stephen J Murphy; Soon T Lim; Justin A Kinsella; Sean Tierney; Bridget Egan; Tim M Feeley; Clare Dooley; James Kelly; Sinead M Murphy; Richard A Walsh; Ronan Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary P Colgan; Jim F Meaney; George Hamilton; Dominick Jh McCabe
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-11       Impact factor: 6.200

5.  Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis.

Authors:  S J X Murphy; S T Lim; J A Kinsella; S Tierney; B Egan; T M Feeley; S M Murphy; R A Walsh; D R Collins; T Coughlan; D O'Neill; J A Harbison; P Madhavan; S M O'Neill; M P Colgan; D Cox; N Moran; G Hamilton; J F Meaney; D J H McCabe
Journal:  J Neurol       Date:  2019-10-12       Impact factor: 4.849

6.  Effects of estrogen on platelet reactivity after transient forebrain ischemia in rats.

Authors:  Marguerite T Littleton-Kearney; Jessica M Gaines; Kevin P Callahan; Stephanie J Murphy; Patricia D Hurn
Journal:  Biol Res Nurs       Date:  2005-10       Impact factor: 2.522

7.  Longitudinal assessment of thrombin generation potential in response to alteration of antiplatelet therapy after TIA or ischaemic stroke.

Authors:  W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R A McGrath; D R Collins; T Coughlan; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; Dominick J H McCabe
Journal:  J Neurol       Date:  2012-10-14       Impact factor: 4.849

8.  [Prevalence of acetylsalicylic acid (ASA) - low response in vascular surgery].

Authors:  T Hummel; S H Meves; K Rüdiger; A Mügge; A Mumme; B Burkert; D Mühlberger; H Neubauer
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

9.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

10.  Short-Term Exposure to Waterpipe/Hookah Smoke Triggers a Hyperactive Platelet Activation State and Increases the Risk of Thrombogenesis.

Authors:  Ahmed B Alarabi; Zubair A Karim; Jean E Montes Ramirez; Keziah R Hernandez; Patricia A Lozano; José O Rivera; Fatima Z Alshbool; Fadi T Khasawneh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-16       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.